Organisation: Deloitte

Commercialisation of trade secrets remains elusive for many, but revenue streams are there to be had

At this week’s IAM Live: Trade Secret Strategy Europe eventonly 11% of companies attending said they have an effective process in place to monetise trade secrets. IAM’s Maia Biermann reflects on why 

20 April 2024

Missed opportunities and risks around trade secret management highlighted in new survey

Deloitte’s first study of its kind shows 29% of the respondents do not actively capture trade secrets despite awareness that they can boost competitive advantage

05 January 2024

Nokia-Oppo, IP financing, and India’s courts: APAC's top five of 2023

IAM looks back at the biggest stories from the region over the last 12 months

28 December 2023

IP valuation market gaining new momentum in Japan

Country’s IP disclosure requirement kickstarts demand in otherwise sluggish market

20 October 2023

Patent transactions in Q3 2022

Featured in Secondary Market Activity

Data platform changes at the USPTO may mean transactions are being recorded more slowly than usual, says AST

08 December 2022

Why IP valuation in Asia has yet to take off

Although various government-led programmes have emerged over the years to encourage activity in the field, writes Joyce Ng, professionals reveal that a lack of transaction data and an absence of corporate buy-in is preventing it from going mainstream

22 June 2022

Five key takeaways from IPBC Europe

Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more

02 April 2022

Highlights from the final day of IPBC Europe 2022

Patent value, IP finance and the challenges of digitisation were just some of the subjects discussed in front of a sell-out audience in London yesterday

31 March 2022

How mapping IP and other intangibles can drive business value

The long read: Charting the value of intellectual assets can be difficult, writes Deloitte's Tim Heberden, but there are ways of showing their role as the drivers of revenue, efficiency and risk, and even in locating the value flows between them

14 April 2021

Creative monetisation of de-prioritised IP is the next frontier for Big Pharma strategists

Despite their commitments to specialisation, large life sciences companies must not neglect the value of sidelined patents, know-how and other intangible assets

06 March 2021

Unlock unlimited access to all IAM content